🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Women's Hospital School Of Medicine Zhejiang University clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with Women's Hospital School Of Medicine Zhejiang University as lead sponsor. Synced 26 Sep 2026
28Current trials
21Recruiting now
5Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Women's Hospital School Of Medicine Zhejiang University is the lead sponsor of 28 current clinical trials in our China register. 21 are recruiting patients now. The most common phase is Observational. The drugs named most often in its trials are Camrelizumab, Carboplatin and Ivonescimab. The most-studied condition is Gestational Trophoblastic Neoplasia.

ClinicalTrials.gov trials by status

  • Recruiting2175%
  • Not yet open621%
  • Active, closed14%

Trials by phase

  • Observational1346%
  • Not applicable725%
  • Phase 2414%
  • Phase 3311%
  • Phase EARLY_PHASE114%
01

Clinical trials sponsored by Women's Hospital School Of Medicine Zhejiang University

28 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Clinical Value of ETCOc in the Diagnosis and Treatment of ABO-HDN
NCT05842109 · ClinicalTrials.gov ↗ · ABO Hemolytic Disease of Newborn
Observational Recruiting 2023-10 China
Prospective Study for Endometrial Carcinoma and Hyperplasia in Childbearing-age Women
NCT06417736 · ClinicalTrials.gov ↗ · Endometrial Cancer Stage I, Endometrial Hyperplasia
Not applicable Recruiting 2023-12 China
Secondary Cytoreduction Followed by Chemotherapy Versus Chemotherapy Alone in Relapsed Ovarian Cancer After PARPi Maintenance Treatment: a Multicentre, Open-label, Randomised, Phase 3 Trial
NCT05607329 · ClinicalTrials.gov ↗ · Relapsed Ovarian Cancer
Not applicable Recruiting 2021-05 China
Preventive Effect of Probiotics in GDM
NCT06938464 · ClinicalTrials.gov ↗ · Gestational Diabetes Mellitus (GDM)
Not applicable Recruiting 2023-10 China
Clinical Efficacy Study of PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Advanced Endometrial Cancer
NCT06561308 · ClinicalTrials.gov ↗ · Endometrioid Endometrial Cancer
Phase 2 Recruiting 2025-09 China
Utility of Whole Genome Sequencing in Fetuses With Abnormal Ultrasound Findings
NCT07606989 · ClinicalTrials.gov ↗ · Prenatal Diagnosis, Fetal Diseases
Observational Recruiting 2026-03 China
Clinical Specialty Queue For Gestational Trophoblastic Neoplasia
NCT06681259 · ClinicalTrials.gov ↗ · Gestational Trophoblastic Neoplasia
Observational Recruiting 2024-11 China
Prenatal Cell-free DNA Screening in Pregnancies With Diverse Genetic Risk Profiles Utilizing Targeted and Whole-exome Sequencing
NCT07106853 · ClinicalTrials.gov ↗ · Genetic Disease
Observational Recruiting 2025-09 China
Association of Gestational Cardiovascular Health With Pregnancy Outcomes
NCT05776082 · ClinicalTrials.gov ↗ · Pregnant Women
Observational Recruiting 2023-03 China
Study on the Dynamic Changes of Metabolic Biomarkers and Their Prognostic Relationship in Ovarian Cancer
NCT06019923 · ClinicalTrials.gov ↗ · Ovarian Cancer
Observational Recruiting 2023-10 China
Study of Different Therapeutic Strategies in Hydatidiform Mole With Lung Nodule
NCT03785574 · ClinicalTrials.gov ↗ · Hydatidiform Mole, Gestational Trophoblastic Neoplasia
Not applicable Recruiting 2018-12 China
Chemo-immunotherapy for Cervical Cancer Stage IIICp Trial
NCT07167160 · ClinicalTrials.gov ↗ · Cervical Cancer, Immunochemotherapy
Phase 2 Recruiting 2025-03 China
Modified Diagnosis and Treatment of Neonatal Hemolysis With ETCOc in sNH
NCT06832800 · ClinicalTrials.gov ↗ · Neonatal Hyperbilirubinemia
Phase EARLY_PHASE1 Recruiting 2025-07 China
PROfiling Based Endometrial Cancer Adjuvant Therapy
NCT05179447 · ClinicalTrials.gov ↗ · Endometrial Cancer Stage I, Endometrial Cancer Stage II
Not applicable Recruiting 2022-01 China
Accurate Assessment and Intervention Research on Newborn Whole Genome Sequencing and Genetic Disease Risk
NCT07365254 · ClinicalTrials.gov ↗ · Genetic Disease
Observational Recruiting 2025-02 China
A Cohort Study of Uterine Malignancies
NCT05635123 · ClinicalTrials.gov ↗ · Cervical Cancer, Endometrial Cancer
Observational Recruiting 2023-09 China
Nab-paclitaxel Versus Sb-taxanes As First-Line Treatment in Advanced Ovarian Cancer
NCT05737303 · ClinicalTrials.gov ↗ · Epithelial Ovarian Carcinoma Stage III, Epithelial Ovarian Carcinoma Stage IV, Fallopian Tube Carcinoma Stage III
Phase 3 Recruiting 2023-11 China
The Treatment Outcomes of Cesarean Scar Pregnancy
NCT07608094 · ClinicalTrials.gov ↗ · Cesarean Scar Pregnancy
Observational Recruiting 2025-08 China
A RCT of Labor Induction at 39 Weeks in Low - Risk Women in China
NCT07082530 · ClinicalTrials.gov ↗ · Cesarean Delivery
Not applicable Recruiting 2025-07 China
Study of Hysteroscopic Repeat Curettage as the First-line Treatment in Low-risk Postmolar Gestational Trophoblastic Neoplasia
NCT03703271 · ClinicalTrials.gov ↗ · Gestational Trophoblastic Neoplasia
Phase 3 Recruiting 2019-03 China
A Multicenter Observational Study on the Development and Health Effects of Premature Ovarian Insufficiency
NCT06067529 · ClinicalTrials.gov ↗ · Premature Ovarian Insufficiency
Observational Recruiting 2023-10 China
LIGHT Trial: Levothyroxine for Gestational Hypothyroidism in Recurrent Pregnancy Loss
NCT06999278 · ClinicalTrials.gov ↗ · Abortion, Habitual
Phase 3 Not yet open 2025-06 China
Predicting Treatment Failure in HSIL Patients with Positive Margins After Conization Via Detection of PAX1 Methylation
NCT06713655 · ClinicalTrials.gov ↗ · High-grade Squamous Intraepithelial Lesions (HSIL), Cervical Conization
Observational Not yet open 2024-12 China
Neoadjuvant Ivonescimab Plus Chemotherapy Followed by Concurrent Chemoradiotherapy in High-Risk Locally Advanced Cervical Cancer
NCT07244965 · ClinicalTrials.gov ↗ · LOCALLY ADVANCED CERVICAL CANCERS
Phase 2 Not yet open 2025-12 China
Cytoreductive Surgery in Platinum-resistant Recurrent Ovarian Cancer
NCT05633199 · ClinicalTrials.gov ↗ · Cytoreductive Surgery
Not applicable Not yet open 2022-12 China
An AI-Assisted Agentic System for Ultrasound Scanning and Diagnosis of Ovarian Lesions
NCT07801209 · ClinicalTrials.gov ↗ · Ovarian Mass, Adnexal Mass
Observational Not yet open 2026-08 China
Elemene Liposomes in Endometrial Cancer
NCT07738315 · ClinicalTrials.gov ↗ · Endometrial Carcinoma
Phase 2 Not yet open 2026-08 China
Effect Evaluation of Different Blood Products Infusion on Neonatal Anemia
NCT06285604 · ClinicalTrials.gov ↗ · Neonatal Anemia
Observational Active, closed 2024-09 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Women's Hospital School Of Medicine Zhejiang University trials

5 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Women's Hospital School Of Medicine Zhejiang University trials

34 conditions
Gestational Trophoblastic Neoplasia3Endometrial Cancer Stage I2Genetic Disease2Cervical Cancer2ABO Hemolytic Disease of Newborn1Endometrial Hyperplasia1Relapsed Ovarian Cancer1Gestational Diabetes Mellitus (GDM)1Endometrioid Endometrial Cancer1Prenatal Diagnosis1Fetal Diseases1Abortion, Habitual1Pregnant Women1High-grade Squamous Intraepithelial Lesions (HSIL)1Cervical Conization1LOCALLY ADVANCED CERVICAL CANCERS1Cytoreductive Surgery1Ovarian Mass1Adnexal Mass1Ovarian Cancer1Endometrial Carcinoma1Hydatidiform Mole1Immunochemotherapy1Neonatal Hyperbilirubinemia1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China2821

A trial with sites in more than one country appears in each of those registers.

05

Questions about Women's Hospital School Of Medicine Zhejiang University trials

How many clinical trials does Women's Hospital School Of Medicine Zhejiang University sponsor?

Women's Hospital School Of Medicine Zhejiang University is the lead sponsor of 28 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Women's Hospital School Of Medicine Zhejiang University trials recruiting?

Yes. 21 of its 28 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Women's Hospital School Of Medicine Zhejiang University testing?

Its current trials name 5 drugs and biologicals as interventions. The most frequent are Camrelizumab (2), Carboplatin (1), Ivonescimab (1), Megestrol Acetate (1) and Paclitaxel (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.